Specific T-cells, TCR T-cells, and CAR-T-cells require to establish some
techniques of molecular biology to support them, including screening tumor-associated
antigen (TAA)/tumor specific antigen (TSA) and mutant proteins/peptides;
constructing an expression system; packaging an expression vector. The molecular
biology technique is a very important performance in targeting neoantigens for tumorspecific
T-cells of adoptive T-cell immunotherapy. Since tumor cells often accumulate
hundreds of mutations and harbor several immunogenic neoantigens, the repertoire of
mutant protein or neoantigen from patient tumor cells might need to screen and
discover the antigens for engineering specific T-cells, TCR T-cells, and CAR T-cells.
In order to understand the procedures for T-cell adoptive immunotherapy based on
molecular biology techniques for mutant proteins and neoantigens from an individual
patient, in this chapter, we focus on streamlining of screening tumor antigens (TAA or
TSA) and mutant proteins (proteins or peptides), constructing an expression and
packaging system with the expression. Moreover, because the three T-cells are distinct
from development and clinical application, we first introduce their research and
Development (R&D). These methodologies are increasingly supporting clinical
oncologists to apply to T-cell immunotherapy. The chapter aims to present fundamental
of molecular biology for adoptive T-cell immunotherapy of clinical patients.
Keywords: CAR (chimeric antigen receptor) T-cells, Lentiviral, Monoclonal Ab,
Phage display system, Retroviral vector, Specific T-cells, T-cell adoptive
immunotherapy, TCR (T-cell receptors).
